BioMarin Pharma (BMRN) Presents Updated Vosoritide Phase 2 Data in Achondroplasia; Mean Annualized Growth Velocity Similar to Lower Dose
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
